Novo Nordisk Makes $9 Billion Bid for Metsera, Topping Pfizer's Offer
Novo Nordisk offers $77.75/share for Metsera in $9B deal, beating Pfizer's bid. Two-step structure includes immediate $56.50 dividend + milestone payments.
/ 88 items
#NVO↓
Novo Nordisk Challenges Pfizer's $4.9B Deal for Obesity Startup Metsera
Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.
Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results
Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.
Oral VTX3232 Study Reveals Significant Reductions in Inflammatory Cardiovascular Risk Markers
Ventyx Biosciences' VTX3232 demonstrates significant reduction in heart disease risk markers in Phase 2 trial, with strong anti-inflammatory effects and good safety profile.
Citi Upgrades BioAge Labs Stock on Promising Obesity Drug Potential
Citi analyst upgrades BioAge Labs to Buy with $10 price target, citing BGE-102 obesity drug as potentially game-changing treatment option.
Novo Nordisk Chairman and Six Directors Resign Amid Foundation Power Struggle
Novo Nordisk's chairman Helge Lund and six independent directors are stepping down after failing to reach agreement with majority shareholder over pace of board transformation as company faces market challenges.